CC
KYMR icon

Checkpoint Capital’s Kymera Therapeutics KYMR Stock Holding History

Checkpoint Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-61,750
Closed -$3.5M – 9
2025
Q3 		$3.5M Sell
61,750
-45,241
-42% -$2.04M 1.17% 9
2025
Q2 		$4.67M Sell
106,991
-29,614
-22% -$1.02M 2.18% 7
2025
Q1 		$3.74M Buy
136,605
+59,070
+76% +$2.15M 2.05% 9
2024
Q4 		$3.12M Buy
+77,535
New +$3.5M 1.59% 14
2024
Q3 		– Sell
-82,000
Closed -$2.45M – 19
2024
Q2 		$2.45M Buy
+82,000
New +$2.84M 1.48% 11

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Checkpoint Capital's KYMR Position: Q4 2025 in Review

Checkpoint Capital sold out of Kymera Therapeutics (KYMR) in Q4 2025, closing a stake of 61,750 shares — an estimated $3.5M sold.

Checkpoint Capital first reported a position in KYMR in Q2 2024 and held it in 5 quarters. The position peaked at $4.67M in Q2 2025. 254 funds tracked by Wall St. Rank hold KYMR as of Q4 2025.

  • Checkpoint Capital reported no remaining Kymera Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Checkpoint Capital sold 61,750 Kymera Therapeutics shares in Q4 2025, an estimated $3.5M.
  • Checkpoint Capital first reported a position in Kymera Therapeutics in Q2 2024 and held it in 5 quarters.
  • Checkpoint Capital's Kymera Therapeutics position peaked at $4.67M in Q2 2025.
  • 254 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2025.

Based on Checkpoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.